Moreover, in a recent study, a molecular docking approach was described to verify Que multi-targeting potential against selected glioma targets, namely, epidermal growth factor receptor (EGFR), ephrin type-A receptor 2 (EphA2), nicotinamide phosphoribosyltransferase (NMRPTase), and plasminogen activator inhibitor-1 (PAI-1). This evidence concerns the gene SERPINE1 and central nervous system cancer.